Ian Parish
LightNews LightNews
banner
ianparish.bsky.social
Ian Parish
@ianparish.bsky.social
420 followers 110 following 8 posts
Immunologist & Group Leader at the Peter MacCallum Cancer Centre. Views are my own.

https://www.petermac.org/research/research-programs-and-labs/cancer-immunology-program/ian-parish-lab
Posts Replies Media Videos
Reposted by Ian Parish
roychoudhurilab.bsky.social
Delighted to share new work published in
@science.org entitled 'Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species,' led by @xanwesolowski.bsky.social
in the lab science.org/eprint/YQNFA...
September 4, 2026 at 10:30 AM
Reposted by Ian Parish
labwaggoner.bsky.social
A high-fibre diet-derived microbial polyphenol metabolite boosts T-cell stemness in cancer immunotherapy @natnano.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
August 11, 2026 at 8:43 PM
Reposted by Ian Parish
petermaccc.bsky.social
A “precision guided” CAR T-cell therapy designed at Peter Mac to kill solid tumours will progress to a first-in-human clinical trial thanks to almost $18 million from @ausgov.

More: www.petermac.org/about-us/new...

#CARTCellTherapy #Immunotherapy
July 16, 2026 at 1:00 AM
Reposted by Ian Parish
ajithvasanthan.bsky.social
I’m excited to share our latest study, published today in @natimmunol.nature.com. It is long known that pregnancy reduces the risk of developing breast cancer, yet the biological mechanisms underlying this protection have remained largely unknown.

Read the paper here: www.nature.com/articles/s41...
Pregnancy-induced tissue-resident memory-like T cells contribute to tumor control in breast cancer - Nature Immunology
Here the authors identify an abundance of a tissue-resident memory-like T cell population in the breasts of women who have given birth. These cells can contribute to tumor control and may thereby prov...
www.nature.com
July 3, 2026 at 10:03 AM
Reposted by Ian Parish
danielutzschneider.bsky.social
Thrilled to share our newest study led by @categraca.bsky.social and @yannick-alexandre.bsky.social published in @cp-immunity.bsky.social

Here, we identify B cells as critical helpers for T cells to obtain effector function through enhancing IFN-I 😳

url.au.m.mimecastprotect.com/s/NE67C6X1Py...
July 2, 2026 at 10:09 PM
Reposted by Ian Parish
🚨 We’re hiring!
We’re looking for a Research Assistant / Junior Postdoc to join the Christie Lab at @petermaccc.bsky.social
Ideally the candidate will have experience in analysis of single cell/nuclei RNA sequencing, and be capable of developing bioinformatics workflows and statistical analysis.
June 2, 2026 at 12:03 AM
ianparish.bsky.social
Registration & abstracts closing soon for the 1st International Conference on T cells in Health & Disease in Crete, a new conference series in a great location.

Plenty of trainee travel awards available but attendance spots are limited so register now: aegeanconferences.org/conferences/...
June 1, 2026 at 12:55 PM
Reposted by Ian Parish
danielutzschneider.bsky.social
Do you like beach, summer, Greek food AND T cells???

Then please join us for the 1st Aegean conference on T cells in health and disease

aegeanconferences.org/conferences/...

Registration closes soon (June 15th)!!!
May 26, 2026 at 4:11 AM
Reposted by Ian Parish
roychoudhurilab.bsky.social
Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com

Love the title: BACH2 the future!
www.nature.com/articles/s41...
February 26, 2026 at 6:52 PM
Reposted by Ian Parish
openboxscience.bsky.social
NOW ON YOUTUBE
youtu.be/5OHRntr_McU

'Understanding CD8+ T cell Tolerance'

Ian Parish, PhD
Assoc. Professor & Group Leader,
Peter MacCallum Cancer Centre
lnkd.in/gkXdZbRy
@IanParish_AU

🎙️@dmcmanus123

Thursday, Feb 19th, 2026
5pm ET | 4pm CT | 2pm PT
Zoom👇️
lnkd.in/gQime6rC
February 24, 2026 at 6:40 PM
ianparish.bsky.social
TCF1 is a master regulator of T cell stemness – but can it make exhausted cells go backwards?

We setup a CRISPR KI system to ask this question, and the answer was unexpected.

www.nature.com/articles/s41...
High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion - Nature Communications
Exhaustion is a functional state that hampers anti-cancer and antiviral CD8 T cell activity, and is preceded by a stem-like state, maintained by the transcription factor TCF1. Here authors develop mou...
www.nature.com
February 18, 2026 at 11:51 AM
Reposted by Ian Parish
labwaggoner.bsky.social
High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion @natcomms.nature.com @ianparish.bsky.social @petermaccc.bsky.social @paulbeavis4.bsky.social
www.nature.com/articles/s41...
February 17, 2026 at 7:48 PM
Reposted by Ian Parish
openboxscience.bsky.social
OBS Immunology | Young Investigator Seminar

'Understanding CD8+ T cell Tolerance'

Ian Parish, PhD
Assoc. Professor & Group Leader,
Peter MacCallum Cancer Centre
tinyurl.com/Parish-Lab
@ianparish.bsky.social

🎙️@danmcmanus123.bsky.social

Thursday, Feb 19th, 2026
5pm ET | 4pm CT | 2pm PT
Zoom👇️
February 13, 2026 at 4:35 PM
Reposted by Ian Parish
tcellogic.bsky.social
New study—and exciting collaboration with Wei Wang, Cong Liu (UCSD), and Kay Chung (new lab at UNC)—that provides a platform for designing T cells into specific states. We identified state-selective TFs for CD8 T cell states that enable “recipes” for cell engineering! www.nature.com/articles/s41...
Atlas-guided discovery of transcription factors for T cell programming - Nature
A comprehensive atlas platform integrating transcriptional and epigenetic data enables more precise engineering of T cell states, accelerating the rational design of more effective cellular immunother...
www.nature.com
February 6, 2026 at 4:40 PM
Reposted by Ian Parish
roychoudhurilab.bsky.social
A great piece in ACIR discussing the there papers on #BACH2 dosing for T cell therapy of cancer recently out in
@NatImmunol
bit.ly/3atHQyV
February 4, 2026 at 9:26 PM
Reposted by Ian Parish
jaehyukchoimd.bsky.social
We have an active search for tenure-track faculty interested in #ImmuneEngineering #ProteinEngineering #GenomeEngineering & #CancerImmunology. Join the newly formed Center for Cellular Therapies and Cancer Immunology #CCTCI. Learn more at apply.interfolio.com/173562. #facultyjobs
Apply - Interfolio {{$ctrl.$state.data.pageTitle}} - Apply - Interfolio
apply.interfolio.com
September 20, 2025 at 12:48 AM
ianparish.bsky.social
Great to see this out, it was fun to work with Roychoudhuri lab on this really nice story. A good illustration that too much "stemness" in T cells can be a bad thing.
roychoudhurilab.bsky.social Roychoudhuri Lab @roychoudhurilab.bsky.social · Jan 16
Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
January 17, 2026 at 10:46 AM
Reposted by Ian Parish
petermaccc.bsky.social
Peter Mac has been awarded $7.5M+ in @nhmrc.bsky.social Ideas Grant funding for five innovative projects tackling cancer metastasis, treatment resistance and immunotherapy.

An outstanding result in a highly competitive scheme!

Read more: www.petermac.org/about-us/new...
January 12, 2026 at 5:37 AM
Reposted by Ian Parish
petermaccc.bsky.social
A $5 million @nhmrc grant will help Peter Mac researchers tackle one of cancer’s toughest challenges: advanced, metastatic disease.

The project, led by @belindaparker.bsky.social, will focus on understanding how metastatic cancers evade the immune system.

More: www.petermac.org/about-us/new...
January 7, 2026 at 11:05 PM
Reposted by Ian Parish
monikawolkers.bsky.social
👇See our newest study:
What was supposed to be a control experiment uncovered a new function of mTOR: 3’mediated translation control in primary human T cells, mediated through DDX21. AU-rich elements are required for this effect. Happy reading!
authors.elsevier.com/a/1mDFf3vVUP...
authors.elsevier.com
December 5, 2025 at 8:24 AM
Reposted by Ian Parish
rrutishauser.bsky.social
1/ We are making progress towards finding a cure for HIV. In a trial @UCSF led by Steve Deeks and @michaelpelusomd.bsky.social, 7/10 participants who received a combination of immunotherapies achieved partial control of HIV after stopping antiretroviral therapy (ART).🧵 www.nature.com/articles/s41...
Correlates of HIV-1 control after combination immunotherapy - Nature
Nature - Correlates of HIV-1 control after combination immunotherapy
www.nature.com
December 2, 2025 at 6:50 AM
Reposted by Ian Parish
roychoudhurilab.bsky.social
We're hiring! We are looking for a Research Assistant with protein biochemistry skills to develop novel protein-based immunotherapeutics targeting Treg cells in cancer. You'll join
@roychoudhurilab.bsky.social @campathology.bsky.social @crukcamcentre.bsky.social Apply: jobs.cam.ac.uk/job/53219/
November 10, 2025 at 7:40 AM
Reposted by Ian Parish
joshilabyale.bsky.social
Happy to announce the publication using advanced models to understand how T cells mediate efficient immunoediting in early sarcomas.

This was a collaboration between Julie Cheung and Brian Hunt
in the lab

Thanks to Cancer Cell for publishing our work.

www.cell.com/cancer-cell/...
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas
Cheung et al. describe efficient T cell control of nascent neoantigen+ and nearby neoantigen-negative sarcoma cells, underlying a ∼50% reduction in tumor penetrance. This otherwise imperceptible immun...
www.cell.com
October 2, 2025 at 4:50 PM
Reposted by Ian Parish
groomlab.bsky.social
Thrilled to have our latest research @wehi-research.bsky.social published in @natimmunol.nature.com
www.nature.com/articles/s41...

This work was an outstanding partnership between talented PhD student Len Dalit (now postdoc, no 🦋) and bioinformatician @chinweetan.bsky.social

Thread below...
Divergent cytokine and transcriptional signatures control functional T follicular helper cell heterogeneity - Nature Immunology
Dalit, Tan and colleagues provide a multiomic profile of T follicular helper (TFH) cells responses to diverse pathogens, revealing a blueprint for transcriptional flexibility and new tools to interrog...
www.nature.com
September 12, 2025 at 2:20 AM